Pneumococcal vaccine GSK 2189242A (LD formulation 1)

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, Streptococcal

Phase 2

Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants

CompletedNCT01204658

GlaxoSmithKlineInfections, Streptococcal

Start: 2010-09-27End: 2012-10-01Updated: 2019-05-29

Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants

CompletedNCT01262872

GlaxoSmithKlineInfections, Streptococcal

Start: 2011-02-09End: 2013-03-18Updated: 2019-06-19

Related Papers

Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.

2019-04-0838 citations

Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines – A phase II, randomised, observer-blind study in Gambian infants

Vaccine2019-04-0823 citations

Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study

Vaccine2018-07-2517 citations

Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.

2017-07-1717 citations

Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study

Vaccine2017-04-0480 citations